Keith Murphy, Founder and Chief Executive Officer. Prior to developing Viscient, Mr. Murphy co-founded Organovo, the world's premier 3D Bioprinting company of which he is the former CEO and Chairman Emeritus, in 2007 and led all company operations until 2017. He co-invented the NovoGen MMX bioprinter platform and grew Organovo through early investments and corporate partnerships, including major alliances with Astellas and Merck. The company started trading on NYSE in 2013, and since going public the company has focused on the development of three-dimensional liver, kidney, and cancer tissues. The most advanced program, liver tissue, has grown to encompass a range of applications from commercial use for pharmaceutical toxicology prediction to the preclinical development of human 3D liver patches for transplant patients. Prior to co-founding Organovo, Mr. Murphy spent ten years at Amgen in roles of increasing responsibility, including four years as the Global Operations Leader of denosumab, now marketed as Prolia & Xgeva ($3B+ annual sales). He holds a B.S. in chemical engineering from the Massachusetts Institute of Technology and is an alumnus of the UCLA Anderson School of Management. Mr. Murphy serves on the Board of the California Life Sciences Association and Adgero Biopharmaceuticals.
Jeffrey N. Miner, Founder and Chief Scientific Officer. Prior to Viscient, Dr. Miner held research leadership positions at Ardea Biosciences, a member of the Astrazeneca group, and Ligand Pharmaceuticals. His responsibilities at Ardea covered the Biology program as it relates to discovery, preclinical, translational and clinical development. He was head of molecular and cellular biology at Ligand pharmaceuticals. He is a Faculty Advisor and Molecular Biology Institute Associate at San Diego State University and is a scientific advisory board member for ARTA Bioscience. His Ph.D. graduate work was conducted in virology at Oregon State University with a post-doctoral fellowship at the University of California San Francisco in glucocorticoid gene regulation. He has drug discovery experience in the Inflammation, Oncology, Endocrine and Cardiovascular drug discovery therapeutic areas and his work has led to or enhanced the development of multiple marketed compounds. His target expertise includes Nuclear Receptors, Kinases and Transporters. He has published over 60 peer reviewed articles and book chapters and is an inventor on multiple patents.